Navigation Links
New approach to BSE successful in lab

A new method of treatment can appreciably slow down the progress of the fatal brain disease scrapie in mice. This has been established by researchers from the Universities of Munich and Bonn together with their colleagues at the Max Planck Institute in Martinsried. To do this they used an effect discovered by the US researchers Craig Mello and Andrew Fire, for which they were awarded this year’s Nobel Prize for Medicine. Scrapie is a variant of the cattle disease BSE and the human equivalent Creutzfeld-Jakob disease. However, it will take years for the method to be introduced to medicine, the researchers warn. Their findings are published in the next issue of the Journal of Clinical Investigation (Vol. 116, No. 12, December 2006).

Scrapie, Creutzfeld-Jakob and BSE are among the most unusual diseases known to medical research. Unusual because the pathogens are apparently neither viruses nor bacteria, being simply protein molecules known as protein prions. What is even more peculiar: exactly the same prion proteins occur in healthy animals. The only difference is that they have a different shape. When there is contact with their ‘diseased twins?they change their shape, also becoming ‘diseased.?The result is an irresistible chain reaction. The malformed prion proteins can be deposited in the brain, thereby destroying brain tissue. Prion diseases are always fatal, often, however, not until months after the outbreak of the disease. As yet there is no cure.

In mice suffering from scrapie the pathogenic prion protein is known as PrP-Scr, whereas the normal variant is PrP-C. PrP-C seems to have a protective effect in diseases like a stroke. Interestingly, mice which cannot produce any PrP-C appear to be completely healthy. This has become the starting point for a new therapeutic approach which for some years now has been current in research circles: can we not simply switch off the production of ‘healthy?PrP-C in infected animals, thereby depriving the ‘di seased?PrP-Scr of its ability to spread" In this way the chain reaction would be interrupted.

New therapeutic approach

Scientists from Munich’s Ludwig Maximilian University and the University of Bonn, in conjunction with colleagues from the Max Planck Institute in Martinsried, have been testing whether this approach works. In doing so they cut back the production of PrP-C in mice by means of an ingenious procedure. The researchers used a special RNA molecule for this purpose. RNA is related to the genetic molecule DNA. There are types of RNA known as siRNAs which can attach themselves to specific genes, thereby preventing these from being ‘read? The production of the appropriate protein is thus shut down. This effect is known as RNA interference; its discovery was rewarded with this year’s Nobel Prize for Medicine. “We modified the brain cells of mice in such a way that they were able to produce siRNAs in place of the ‘healthy?PrP-C protein,?explains Professor Alexander Pfeifer, director of the Institute of Pharmacology of the University of Bonn. “In cell cultures the production of PrP-C was thereby cut back by up to 97 per cent.?

The researchers then tested what effect these siRNAs had on mice which had scrapie. ‘If brain cells are to produce siRNAs, you have to smuggle in the corresponding gene,?says Professor Kretschmar, director of the Prion Centre of Munich’s Ludwig Maximilian University. ‘But presumably we’ll never manage to equip all the cells in the brain with this gene.?This is why the researchers also wanted to find out how many cells they have to ‘revamp?genetically to treat scrapie or similar diseases successfully. For this purpose they bred mice that only had some brain cells which could produce siRNAs. ‘Whereas the untreated mice died on average after 165 days, the mice which had been treated lived appreciably longer,?is how Professor Kretschmar summarises the results.

BSE-resistant cattle"

It varied ho w much longer they lived: if only a few cells could produce siRNAs, the mice died at almost the same time as the control mice, i.e. on average after 170 days. However, if the majority of the brain cells were protected by siRNA, the mice survived the prion disease for up to 230 days, in other words about a third longer.

‘Basically siRNAs seem to be a promising therapeutic option for scrapie, CJD or BSE,?Professor Pfeifer emphasises. ‘However, it will take years before the method can be used on human beings.?The method is also relevant for animal breeding: in principle it can be used to breed cattle which cannot produce any PrP-C. They would then be resistant to BSE.
'"/>

Source:University of Bonn


Related biology news :

1. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
2. MSI releases moleculizer - a new approach to simulation of intracellular biochemical networks
3. Stopping smallpox in its tracks: A new anti-viral approach
4. Building a protein name dictionary from full text: a machine learning term extraction approach
5. Rensselaer researchers develop approach that predicts protein separation behavior
6. Huntingtons cure in flies lays groundwork for broader treatment approaches
7. Results of worlds first gene therapy trial for arthritis show approach safe, feasible
8. Vaginal gel may provide a new approach to HIV prevention
9. Clinical trial to test stem cell approach for children with brain injury
10. Study in Science holds promise for a new approach to drug therapy
11. U-M researchers take new approach to defeating Gram-negative bugs

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/9/2016)... March 9, 2016 This BCC Research report ... of the RNA Sequencing (RNA Seq) market for the ... instruments, tools and reagents, data analysis, and services. ... of the RNA-Sequencing market such as RNA-Sequencing tools and ... main factors affecting each segment and forecast their market ...
(Date:3/3/2016)... Calif. , March 3, 2016  FlexTech, a ... the categories of Innovation, Research & Development, Leadership in ... Leadership. This is the 9 th year of ... group of companies and individuals from past years ... based on a pre-described set of criteria, by a ...
(Date:3/2/2016)... http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has ... Biometrics as a Service Market 2016-2020" ... http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the addition ... Service Market 2016-2020" report to their ... Markets ( http://www.researchandmarkets.com/research/cmt3hk/global_biometrics ) has announced the ...
Breaking Biology News(10 mins):
(Date:5/5/2016)... ... May 05, 2016 , ... ProMIS Neurosciences (“ProMIS” or the ... targets, it has identified a fourth in a series of novel potential therapeutic ... progression of Alzheimer’s disease (AD). , “This discovery is an important ...
(Date:5/4/2016)... May 4, 2016  Bayer today announced that ... Stivarga ® (regorafenib) tablets for the treatment ... met its primary endpoint of a statistically significant ... evaluated the efficacy and safety of regorafenib in ... treatment with sorafenib. The safety and tolerability were ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, a first-to-market ... treat hormonal and stress related hair loss. With patent-pending formulas for both female ... opinion leaders in the medical and salon channels nationwide. , Dermatologists, Plastic ...
(Date:5/3/2016)... ... May 03, 2016 , ... Leading CEOs from biotech, ... 31st and June 1st at The Four Seasons Hotel Boston. , The Boston ... sciences, offering exclusive access to key decision makers who influence deal making and ...
Breaking Biology Technology: